Photo by aaronburden from unsplash
The article “Phase 3 Study of OnabotulinumtoxinA Distributed between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines” is timely given the relatively recent FDA-approved indication… Click to show full abstract
The article “Phase 3 Study of OnabotulinumtoxinA Distributed between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines” is timely given the relatively recent FDA-approved indication of this toxin for horizontal forehead lines. Onabotulinum toxin was FDA approved for glabellar lines in 2002 and for lateral canthal lines in 2014. In light of the approval of this toxin in all 3 areas of the upper face, this article provides support for treating all sites at one time, a common practice in modern aesthetic medicine.
Journal Title: Dermatologic Surgery
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!